Journal of Cancer Research and Clinical Oncology

, Volume 143, Issue 2, pp 233–241 | Cite as

Quantitative proteome analysis of colorectal cancer-related differential proteins

  • Yanbin Zhang
  • Yue Liu
  • Yingjiang Ye
  • Danhua Shen
  • Hui Zhang
  • Hongyan Huang
  • Sha Li
  • Shan Wang
  • Jun RenEmail author
Original Article – Cancer Research



To evaluate a new strategy for profiling proteomic changes in colorectal cancer (CRC).


We used laser capture microdissection (LCM) to obtain cells from 20 CRC and paired normal mucosal tissues. The differential proteins between the microdissected tumor cells and normal mucosa epithelia were analyzed by acetylation stable isotopic labeling coupled with L linear ion trap Fourier transform ion cyclotron resonance mass spectrometry (LTQ-FT MS). Western blotting was used to assess the differential expression of proteins. We used bioinformatics tools for cluster and ingenuity pathway analysis of the differential proteins.


In total, 798 confident proteins were quantified and 137 proteins were differentially expressed by at least twofold, including 67 that were upregulated and 70 that were downregulated in cancer. Two differential proteins, solute carrier family 12 member 2 (SLC12A2) and Ras-related protein Rab-10, were validated by Western blotting, and the results were consistent with acetylation stable isotopic labeling analysis. According to gene ontology analysis, CRC-related differential proteins covered a wide range of subcellular locations and were involved in many biological processes. According to ingenuity pathway analysis of the differential proteins, the most relevant canonical pathway associated with CRC was the 14-3-3-mediated signaling pathway, and seven reliable functional networks including cellular growth and proliferation, amino acid metabolism, inflammatory response, embryonic development, carbohydrate metabolism, cellular assembly and organization, and cell morphology were obtained.


Combination of LCM, acetylation stable isotopic labeling analysis and LTQ-FT MS is effective for profiling proteomic changes in CRC cells.


Colorectal cancer Quantitative proteomics Laser capture microdissection Acetylation stable isotopic labeling 



We thank Xiaohong Qian and Xin Liu from Beijing Proteome Research Center for their technical assistance.


This study was supported by Beijing Postdoctoral Research Foundation. The funder played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors have stated that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

432_2016_2274_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 34 kb)
432_2016_2274_MOESM2_ESM.docx (15 kb)
Supplementary material 2 (DOCX 15 kb)


  1. Becchetti A, Munaron L, Arcangeli A (2013) The role of ion channels and transporters in cell proliferation and cancer. Front Physiol 4:312CrossRefPubMedPubMedCentralGoogle Scholar
  2. Berretta M, Lleshi A, Zanet E et al (2008) Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. Onkologie 31:394–397CrossRefPubMedGoogle Scholar
  3. Bi X, Lin Q, Foo TW et al (2006) Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol Cell Proteom 5:1119–1130CrossRefGoogle Scholar
  4. Carpelan-Holmström M, Louhimo J, Stenman UH et al (2004) CEA, CA 242, CA 19-9, CA 72-4 and hCG beta in the diagnosis of recurrent colorectal cancer. Tumour Biol 25:228–234CrossRefPubMedGoogle Scholar
  5. Cheng AL, Huang WG, Chen ZC et al (2008) Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis. J Proteome Res 7:2415–2426CrossRefPubMedGoogle Scholar
  6. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMedGoogle Scholar
  7. Datta S, Malhotra L, Dickerson R et al (2015) Laser capture microdissection: big data from small samples. Histol Histopathol 30:1255–1269PubMedPubMedCentralGoogle Scholar
  8. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047CrossRefPubMedGoogle Scholar
  9. Duncan R, Carpenter B, Main LC et al (2008) Characterization and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98:426–433CrossRefPubMedGoogle Scholar
  10. Dundas SR, Lawrie LC, Rooney PH, Murray GI (2005) Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 205:74–81CrossRefPubMedGoogle Scholar
  11. Everley PA, Bakalarski CE, Elias JE et al (2006) Enhanced analysis of metastatic prostate cancer using stable isotopics and high mass accuracy instrumentation. J Proteome Res 5:1224–1231CrossRefPubMedGoogle Scholar
  12. Fakih MG, Padmanabhan A (2006) CEA monitoring in colorectal cancer. What you should know. Oncology 20:579–587PubMedGoogle Scholar
  13. Grotowski M (2002) Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer. Pol Merkur Lekarski 12:77–80PubMedGoogle Scholar
  14. Gygi SP, Corthals GL, Zhang Y et al (2000) Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97:9390–9395CrossRefPubMedPubMedCentralGoogle Scholar
  15. Haas BR, Sontheimer H (2010) Inhibition of the Sodium-Potassium-Chloride Cotransporter Isoform-1 reduces glioma invasion. Cancer Res 70:5597–5606CrossRefPubMedPubMedCentralGoogle Scholar
  16. Hanash S (2003) Disease proteomics. Nature 422:226–232CrossRefPubMedGoogle Scholar
  17. Krausova M, Korinek V (2012) Signal transduction pathways participating in homeostasis and malignant transformation of the intestinal tissue. Neoplasma 59:708–718CrossRefPubMedGoogle Scholar
  18. Li N, Zhang J, Liang Y et al (2007) A controversial tumor marker: is SM22 a proper biomarker for gastric cancer cells? J Proteome Res 6:3304–3312CrossRefPubMedGoogle Scholar
  19. Li T, Yang W, Li M et al (2008) Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Mol Nutr Food Res 52:1289–1299CrossRefPubMedGoogle Scholar
  20. Melle C, Bogumil R, Ernst G et al (2006) Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics 6:2600–2608CrossRefPubMedGoogle Scholar
  21. Murata T, Takayama K, Urano T et al (2012) 14-3-3zeta, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res 18:5617–5627CrossRefPubMedGoogle Scholar
  22. Nicolini A, Ferrari P, Duffy MJ et al (2010) Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Arch Surg 145:1177–1183CrossRefPubMedGoogle Scholar
  23. Nuan J, Xin I, Jun W et al (2007) A proteomic method for analysis of CYP450 s protein expression changes in carbon tetrachloride induced male rat liver microsomes. Toxicology 237:1–11CrossRefGoogle Scholar
  24. Panagopoulos K, Cross-Knorr S, Dillard C et al (2013) Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer 12:118CrossRefPubMedPubMedCentralGoogle Scholar
  25. Popa-Velea O, Cernat B, Tambu A (2010) Influence of personalized therapeutic approach on quality of life and psychiatric comorbidity in patients with advanced colonic cancer requiring palliative care. J Med Life 3:343–347PubMedPubMedCentralGoogle Scholar
  26. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64:9–29CrossRefPubMedGoogle Scholar
  27. Stulík J, Osterreicher J, Koupilová K et al (2000) Differential expression of the Ca2 + binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa. Eur J Cancer 36:1050–1059CrossRefPubMedGoogle Scholar
  28. Sun W, Gao S, Wang L et al (2006) Microwave assisted protein preparation and enzymatic digestion in proteomics. Mol Cell Proteom 5:769–776CrossRefGoogle Scholar
  29. Umar A, Luider TM, Foekens JA, Pasa-Tolić L (2007) NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells. Proteomics 7:323–329CrossRefPubMedGoogle Scholar
  30. Wang Z, Nesland JM, Suo Z et al (2011) The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3beta and epsilon are independent prognostic factors for these tumors. PLoS ONE 6:e24843CrossRefPubMedPubMedCentralGoogle Scholar
  31. Wheeler DB, Zoncu R, Root DE et al (2015) Identification of an oncogenic RAB protein. Science 350:211–217CrossRefPubMedPubMedCentralGoogle Scholar
  32. Yonemori H, Kubota D, Taniguchi H et al (2013) Laser microdissection and two-dimensional difference gel electrophoresis with alkaline isoelectric point immobiline gel reveals proteomic intra-tumor heterogeneity in colorectal cancer. EuPA Open Proteom 1:17–29CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Yanbin Zhang
    • 1
  • Yue Liu
    • 1
  • Yingjiang Ye
    • 2
  • Danhua Shen
    • 2
  • Hui Zhang
    • 2
  • Hongyan Huang
    • 1
  • Sha Li
    • 1
  • Shan Wang
    • 2
  • Jun Ren
    • 1
    Email author
  1. 1.Beijing Key Lab for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan HospitalThe Capital Medical UniversityBeijingChina
  2. 2.Department of Gastrointestinal Surgery, Peking University People’s HospitalPeking UniversityBeijingChina

Personalised recommendations